MLTX · CIK 0001821586 · operating
MoonLake Immunotherapeutics is a clinical-stage biotechnology company developing therapies for inflammatory diseases affecting skin and joints. The company's primary focus is Sonelokimab, a tri-specific Nanobody designed to inhibit both IL-17A and IL-17F, targeting conditions including psoriasis, psoriatic arthritis, axial spondyloarthritis, hidradenitis suppurativa, and palmoplantar pustulosis. The company operates in the pharmaceutical preparations sector and is incorporated in the Cayman Islands with headquarters in Zug, Switzerland.
The company was founded in 2021 and operates as a private clinical-stage entity, meaning it does not currently generate commercial revenue from approved products. MoonLake is listed on the Nasdaq exchange with a market capitalization of approximately $1.2 billion. The company maintains a lean operational structure with 130 full-time employees, consistent with its stage of development focused on clinical advancement rather than commercial-scale manufacturing or distribution.
Fiscal years are as reported by the company and may not align with the calendar year. For example, Apple's FY 2024 ends in September 2024.
| Fiscal Year | EPS Diluted | EPS Basic | YoY | |
|---|---|---|---|---|
| 2025 | $-3.53 | $-3.53 | -86.8% | |
| 2024 | $-1.89 | $-1.89 | -158.9% | |
| 2023 | $-0.73 | $-0.73 | +57.1% | |
| 2022 | $-1.70 | $-1.70 | — | |
| 2021 | — | — | — | |
| 2020 | — | — | — |
| Report Date | Filed | Accession Number | |
|---|---|---|---|
| 2025-12-31 | 2026-02-25 | 0001821586-26-000002 | SEC ↗ |
| 2024-12-31 | 2025-02-26 | 0001821586-25-000006 | SEC ↗ |
| 2023-12-31 | 2024-02-29 | 0001821586-24-000008 | SEC ↗ |
| 2022-12-31 | 2023-03-20 | 0001821586-23-000007 | SEC ↗ |
| 2021-12-31 | 2022-02-17 | 0001213900-22-008253 | SEC ↗ |
| 2020-12-31 | 2021-03-31 | 0001213900-21-019007 | SEC ↗ |